Value through Innovation27 July 2016

Clinical Study Results

  • Tiotropium + BI 54903 - Asthma
    Clinical Study Number 1298.3
    Study Indication Asthma
    Product Tiotropium + BI 54903
    Generic Name Tiotropium + BI 54903
    Lab Code
    Clinical Phase II
    Study Title

    A single dose, randomised, placebo-controlled, double-blind, 5-way crossover (employing an incomplete block design), efficacy (including 24-h pulmonary function tests) and safety comparison of Tiotropium/BI 54903 FDC ethanolic inhalation solution via Respimat® (doses of 1.23 μg/363.6 μg, 2.46 μg/363.6 μg or 4.93 μg/363.6 μg) versus free combination of Tiotropium aqueous inhalation solution via Respimat® (doses of 0, 2.5 μg, 5 μg or 10 μg) plus BI 54903 ethanolic inhalation solution via Respimat® (dose of 363.6 μg ) in patients with asthma

    Study Document Trial statement 1298.3 english

Clinical Trial Registry and structured study results. Find here protocol information for all clinical study types.

European Trial Register of EU studies.